Extrarenal 1α-hydroxylase

Vitamin D

Volumn , Issue , 2011, Pages 777-804

  Hewison, Martin ^a   Adams, John S ^a  

^a JOINT REPLACEMENT INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861322964     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381978-9.10045-9     Document Type: Chapter

References (297)

1. Harrell G.T., Fisher S. Blood chemical changes in Boeck's sarcoid with particular reference to protein, calcium and phosphatase values. J. Clin. Invest. 1939, 18:687-693.
2. Albright F., Carroll E.L., Dempsey E.F., Henneman P.H. The cause of hypercalcuria in sarcoid and its treatment with cortisone and sodium phytate. J. Clin. Invest. 1956, 35:1229-1242.
3. Taylor R.L., Lynch H.J., Wysor W.G. Seasonal influence of sunlight on the hypercalcemia of sarcoidosis. Am. J. Med. 1963, 34:221-227.
4. Dent C.E., Flynn F.V., Nabarro J.D. Hypercalcaemia and impairment of renal function in generalized sarcoidosis. Br. Med. J. 1953, 2:808-810.
5. Bell N.H.G.J.J., Barter F.C. Abnormal calcium absorption in sarcoidosis: evidence for increased sensitivity to vitamin D. Am. J. Med. 1964, 36:500-513.
6. Holick M.F., Schnoes H.K., DeLuca H.F., Suda T., Cousins R.J. Isolation and identification of 1,25-dihydroxycholecalciferol. A metabolite of vitamin D active in intestine. Biochemistry 1971, 10:2799-2804.
7. Lawson D.E., Fraser D.R., Kodicek E., Morris H.R., Williams D.H. Identification of 1,25-dihydroxycholecalciferol, a new kidney hormone controlling calcium metabolism. Nature 1971, 230:228-230.
8. Norman A.W., Myrtle J.F., Midgett R.J., Nowicki H.G., Williams V., Popjak G. 1,25-Dihydroxycholecalciferol: identification of the proposed active form of vitamin D3 in the intestine. Science 1971, 173:51-54.
9. Hughes M.R., Baylink D.J., Jones P.G., Haussler M.R. Radioligand receptor assay for 25-hydroxyvitamin D2/D3 and 1 alpha, 25-dihydroxyvitamin D2/D3. J. Clin. Invest. 1976, 58:61-70.
10. Clemens T.L., Hendy G.N., Graham R.F., Baggiolini E.G., Uskokovic M.R., O'Riordan J.L. A radioimmunoassay for 1,25-dihydroxycholecalciferol. Clin. Sci. Mol. Med. 1978, 54:329-332.
11. Bouillon R., De Moor P., Baggiolini E.G., Uskokovic M.R. A radioimmunoassay for 1,25-dihydroxycholecalciferol. Clin. Chem. 1980, 26:562-567.
12. Holick M.F. The use and interpretation of assays for vitamin D and its metabolites. J. Nutr. 1990, 120(Suppl. 11):1464-1469.
13. Bell N.H., Stern P.H., Pantzer E., Sinha T.K., DeLuca H.F. Evidence that increased circulating 1 alpha, 25-dihydroxyvitamin D is the probable cause for abnormal calcium metabolism in sarcoidosis. J. Clin. Invest. 1979, 64:218-225.
14. Papapoulos S.E., Clemens T.L., Fraher L.J., Lewin I.G., Sandler L.M., O'Riordan J.L. 1, 25-Dihydroxycholecalciferol in the pathogenesis of the hypercalcaemia of sarcoidosis. Lancet 1979, 1:627-630.
15. Stern P.H., De Olazabal J., Bell N.H. Evidence for abnormal regulation of circulating 1 alpha,25-dihydroxyvitamin D in patients with sarcoidosis and normal calcium metabolism. J. Clin. Invest. 1980, 66:852-855.
16. Barbour G.L., Coburn J.W., Slatopolsky E., Norman A.W., Horst R.L. Hypercalcemia in an anephric patient with sarcoidosis: evidence for extrarenal generation of 1,25-dihydroxyvitamin D. N. Engl. J. Med. 1981, 305:440-443.
17. Adams J.S., Sharma O.P., Gacad M.A., Singer F.R. Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. J. Clin. Invest. 1983, 72:1856-1860.
18. Adams J.S., Gacad M.A. Characterization of 1 alpha-hydroxylation of vitamin D3 sterols by cultured alveolar macrophages from patients with sarcoidosis. J. Exp. Med. 1985, 161:755-765.
19. Adams J.S., Singer F.R., Gacad M.A., Sharma O.P., Hayes M.J., Vouros P., et al. Isolation and structural identification of 1,25-dihydroxyvitamin D3 produced by cultured alveolar macrophages in sarcoidosis. J. Clin. Endocrinol. Metab. 1985, 60:960-966.
20. Bell N.H. Endocrine complications of sarcoidosis. Endocrinol. Metab. Clin. North Am. 1991, 20:645-654.
21. Basile J.N., Liel Y., Shary J., Bell N.H. Increased calcium intake does not suppress circulating 1,25-dihydroxyvitamin D in normocalcemic patients with sarcoidosis. J. Clin. Invest. 1993, 91:1396-1398.
22. Sandler L.M., Winearls C.G., Fraher L.J., Clemens T.L., Smith R., O'Riordan J.L. Studies of the hypercalcaemia of sarcoidosis: effect of steroids and exogenous vitamin D3 on the circulating concentrations of 1,25-dihydroxy vitamin D3. Q. J. Med. 1984, 53:165-180.
23. Cronin C.C., Dinneen S.F., O'Mahony M.S., Bredin C.P., O'Sullivan D.J. Precipitation of hypercalcaemia in sarcoidosis by foreign sun holidays: report of four cases. Postgrad. Med. J. 1990, 66:307-309.
24. Insogna K.L., Dreyer B.E., Mitnick M., Ellison A.F., Broadus A.E. Enhanced production rate of 1,25-dihydroxyvitamin D in sarcoidosis. J. Clin. Endocrinol. Metab. 1988, 66:72-75.
25. Shulman L.E., Schoenrich E.H., Harvey A.M. The effects of adrenocorticotropic hormone (ACTH) and cortisone on sarcoidosis. Bull. Johns Hopkins Hosp. 1952, 91:371-415.
26. Anderson J., Harper C., Dent C.E., Philpot G.R. Effect of cortisone on calcium metabolism in sarcoidosis with hypercalcaemia; possibly antagonistic actions of cortisone and vitamin D. Lancet 1954, 267:720-724.
27. O'Leary T.J., Jones G., Yip A., Lohnes D., Cohanim M., Yendt E.R. The effects of chloroquine on serum 1,25-dihydroxyvitamin D and calcium metabolism in sarcoidosis. N. Engl. J. Med. 1986, 315:727-730.
28. Barre P.E., Gascon-Barre M., Meakins J.L., Goltzman D. Hydroxychloroquine treatment of hypercalcemia in a patient with sarcoidosis undergoing hemodialysis. Am. J. Med. 1987, 82:1259-1262.
29. Adams J.S., Sharma O.P., Diz M.M., Endres D.B. Ketoconazole decreases the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia. J. Clin. Endocrinol. Metab. 1990, 70:1090-1095.
30. Adams J.S., Diz M.M., Sharma O.P. Effective reduction in the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia with short-course chloroquine therapy. Ann. Intern. Med. 1989, 111:437-438.
31. Singer F.R., Adams J.S. Abnormal calcium homeostasis in sarcoidosis. N. Engl. J. Med. 1986, 315:755-757.
32. Meyrier A., Valeyre D., Bouillon R., Paillard F., Battesti J.P., Georges R. Resorptive versus absorptive hypercalciuria in sarcoidosis: correlations with 25-hydroxy vitamin D3 and 1,25-dihydroxy vitamin D3 and parameters of disease activity. Q. J. Med. 1985, 54:269-281.
33. Adams J.S., Gacad M.A., Anders A., Endres D.B., Sharma O.P. Biochemical indicators of disordered vitamin D and calcium homeostasis in sarcoidosis. Sarcoidosis 1986, 3:1-6.
34. Smith S.J., Rucka A.K., Berry J.L., Davies M., Mylchreest S., Paterson C.R., et al. Novel mutations in the 1alpha-hydroxylase (P450c1) gene in three families with pseudovitamin D-deficiency rickets resulting in loss of functional enzyme activity in blood-derived macrophages. J. Bone Miner. Res. 1999, 14:730-739.
35. Kallas M., Green F., Hewison M., White C., Kline G. Rare causes of calcitriol-mediated hypercalcemia: a case report and literature review. J. Clin. Endocrinol. Metab 2010, 95:3111-3117.
36. Kantarjian H.M., Saad M.F., Estey E.H., Sellin R.V., Samaan N.A. Hypercalcemia in disseminated candidiasis. Am. J. Med. 1983, 74:721-724.
37. Shai F., Baker R.K., Addrizzo J.R., Wallach S. Hypercalcemia in mycobacterial infection. J. Clin. Endocrinol. Metab. 1972, 34:251-256.
38. Murray J.J., Heim C.R. Hypercalcemia in disseminated histoplasmosis. Aggravation by vitamin D. Am. J. Med. 1985, 78:881-884.
39. Sharma O.P. Vitamin D, calcium, and sarcoidosis. Chest 1996, 109:535-539.
40. Studdy P.R., Bird R., Neville E., James D.G. Biochemical findings in sarcoidosis. J. Clin. Pathol. 1980, 33:528-533.
41. James D.G., Neville E., Siltzbach L.E. A worldwide review of sarcoidosis. Ann. N.Y. Acad. Sci. 1976, 278:321-334.
42. James D.G., Siltzbach L.E., Sharma O.P., Carstairs L.S. A tale of two cities: a comparison of sarcoidosis in London and New York. Arch. Intern. Med. 1969, 123:187-191.
43. Montemurro L., Fraioli P., Rizzato G. Bone loss in untreated longstanding sarcoidosis. Sarcoidosis 1991, 8:29-34.
44. Fallon M.D., Perry H.M., Teitelbaum S.L. Skeletal sarcoidosis with osteopenia. Metab. Bone Dis. Relat. Res. 1981, 3:171-174.
45. Need A.G., Phillips P.J., Chiu F., Prisk H. Hypercalcaemia associated with tuberculosis. Br. Med. J. 1980, 280:831.
46. Felsenfeld A.J., Drezner M.K., Llach F. Hypercalcemia and elevated calcitriol in a maintenance dialysis patient with tuberculosis. Arch. Intern. Med. 1986, 146:1941-1945.
47. Gkonos P.J., London R., Hendler E.D. Hypercalcemia and elevated 1,25-dihydroxyvitamin D levels in a patient with end-stage renal disease and active tuberculosis. N. Engl. J. Med. 1984, 311:1683-1685.
48. Epstein S., Stern P.H., Bell N.H., Dowdeswell I., Turner R.T. Evidence for abnormal regulation of circulating 1 alpha, 25-dihydroxyvitamin D in patients with pulmonary tuberculosis and normal calcium metabolism. Calcif. Tissue Int. 1984, 36:541-544.
49. Bell N.H., Shary J., Shaw S., Turner R.T. Hypercalcemia associated with increased circulating 1,25 dihydroxyvitamin D in a patient with pulmonary tuberculosis. Calcif. Tissue Int. 1985, 37:588-591.
50. Cadranel J., Garabedian M., Milleron B., Guillozo H., Akoun G., Hance A.J. 1,25(OH)2D2 production by T lymphocytes and alveolar macrophages recovered by lavage from normocalcemic patients with tuberculosis. J. Clin. Invest. 1990, 85:1588-1593.
51. Cadranel J.L., Garabedian M., Milleron B., Guillozzo H., Valeyre D., Paillard F., et al. Vitamin D metabolism by alveolar immune cells in tuberculosis: correlation with calcium metabolism and clinical manifestations. Eur. Respir. J. 1994, 7:1103-1110.
52. Isaacs R.D., Nicholson G.I., Holdaway I.M. Miliary tuberculosis with hypercalcaemia and raised vitamin D concentrations. Thorax 1987, 42:555-556.
53. Braman S.S., Goldman A.L., Schwarz M.I. Steroid-responsive hypercalcemia in disseminated bone tuberculosis. Arch. Intern. Med. 1973, 132:269-271.
54. Hoffman V.N., Korzeniowski O.M. Leprosy, hypercalcemia, and elevated serum calcitriol levels. Ann. Intern. Med. 1986, 105:890-891.
55. Ryzen E., Rea T.H., Singer F.R. Hypercalcemia and abnormal 1,25-dihydroxyvitamin D concentrations in leprosy. Am. J. Med. 1988, 84:325-329.
56. Spindel S.J., Hamill R.J., Georghiou P.R., Lacke C.E., Green L.K., Mallette L.E. Case report: vitamin D-mediated hypercalcemia in fungal infections. Am. J. Med. Sci. 1995, 310:71-76.
57. Walker J.V., Baran D., Yakub N., Freeman R.B. Histoplasmosis with hypercalcemia, renal failure, and papillary necrosis. Confusion with sarcoidosis. Jama 1977, 237:1350-1352.
58. Parker M.S., Dokoh S., Woolfenden J.M., Buchsbaum H.W. Hypercalcemia in coccidioidomycosis. Am. J. Med. 1984, 76:341-344.
59. Ahmed B., Jaspan J.B. Case report: hypercalcemia in a patient with AIDS and Pneumocystis carinii pneumonia. Am. J. Med. Sci. 1993, 306:313-316.
60. Kozeny G.A., Barbato A.L., Bansal V.K., Vertuno L.L., Hano J.E. Hypercalcemia associated with silicone-induced granulomas. N. Engl. J. Med. 1984, 311:1103-1105.
61. Jurney T.H. Hypercalcemia in a patient with eosinophilic granuloma. Am. J. Med. 1984, 76:527-528.
62. Edelson G.W., Talpos G.B., Bone H.G. Hypercalcemia associated with Wegener's granulomatosis and hyperparathyroidism: etiology and management. Am. J. Nephrol. 1993, 13:275-277.
63. Al-Ali H., Yabis A.A., Issa E., Salem Z., Tawil A., Khoury N., et al. Hypercalcemia in Langerhans' cell granulomatosis with elevated 1,25 dihydroxyvitamin D (calcitriol) level. Bone 2002, 30:331-334.
64. Stoeckle J.D., Hardy H.L., Weber A.L. Chronic beryllium disease. Long-term follow-up of sixty cases and selective review of the literature. Am. J. Med. 1969, 46:545-561.
65. Cook J.S., Stone M.S., Hansen J.R. Hypercalcemia in association with subcutaneous fat necrosis of the newborn: studies of calcium-regulating hormones. Pediatrics 1992, 90:93-96.
66. Farooque A., Moss C., Zehnder D., Hewison M., Shaw N.J. Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in subcutaneous fat necrosis. Br. J. Dermatol. 2009, 160:423-425.
67. Bosch X. Hypercalcemia due to endogenous overproduction of 1,25-dihydroxyvitamin D in Crohn's disease. Gastroenterology 1998, 114:1061-1065.
68. Abreu M.T., Kantorovich V., Vasiliauskas E.A., Gruntmanis U., Matuk R., Daigle K., et al. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut 2004, 53:1129-1136.
69. Tuohy K.A., Steinman T.I. Hypercalcemia due to excess 1,25-dihydroxyvitamin D in Crohn's disease. Am. J. Kidney Dis. 2005, 45:e3-e6.
70. Jahnsen J., Falch J.A., Mowinckel P., Aadland E. Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 2002, 37:192-199.
71. Zehnder D., Bland R., Williams M.C., McNinch R.W., Howie A.J., Stewart P.M., et al. Extrarenal expression of 25-hydroxyvitamin D(3)-1 alpha-hydroxylase. J. Clin. Endocrinol. Metab. 2001, 86:888-894.
72. Tangpricha V., Flanagan J.N., Whitlatch L.W., Tseng C.C., Chen T.C., Holt P.R., et al. 25-Hydroxyvitamin D-1alpha-hydroxylase in normal and malignant colon tissue. Lancet 2001, 357:1673-1674.
73. Bareis P., Bises G., Bischof M.G., Cross H.S., Peterlik M. 25-Hydroxy-vitamin D metabolism in human colon cancer cells during tumor progression. Biochem. Biophys. Res. Commun. 2001, 285:1012-1017.
74. McCarthy K., Laban C., Bustin S.A., Ogunkolade W., Khalaf S., Carpenter R., et al. Expression of 25-hydroxyvitamin D-1-alpha-hydroxylase, and vitamin D receptor mRNA in normal and malignant breast tissue. Anticancer Res. 2009, 29:155-157.
75. Zaloga G.P., Eil C., Medbery C.A. Humoral hypercalcemia in Hodgkin's disease. Association with elevated 1,25-dihydroxycholecalciferol levels and subperiosteal bone resorption. Arch. Intern. Med. 1985, 145:155-157.
76. Rosenthal N., Insogna K.L., Godsall J.W., Smaldone L., Waldron J.A., Stewart A.F. Elevations in circulating 1,25-dihydroxyvitamin D in three patients with lymphoma-associated hypercalcemia. J. Clin. Endocrinol. Metab. 1985, 60:29-33.
77. Davies M., Mawer E.B., Hayes M.E., Lumb G.A. Abnormal vitamin D metabolism in Hodgkin's lymphoma. Lancet 1985, 1:1186-1188.
78. Adams J.S., Fernandez M., Gacad M.A., Gill P.S., Endres D.B., Rasheed S., et al. Vitamin D metabolite-mediated hypercalcemia and hypercalciuria patients with AIDS- and non-AIDS-associated lymphoma. Blood 1989, 73:235-239.
79. Seymour J.F., Gagel R.F., Hagemeister F.B., Dimopoulos M.A., Cabanillas F. Calcitriol production in hypercalcemic and normocalcemic patients with non-Hodgkin lymphoma. Ann. Intern. Med. 1994, 121:633-640.
80. Seymour J.F., Gagel R.F. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 1993, 82:1383-1394.
81. Davies M., Hayes M.E., Yin J.A., Berry J.L., Mawer E.B. Abnormal synthesis of 1,25-dihydroxyvitamin D in patients with malignant lymphoma. J. Clin. Endocrinol. Metab. 1994, 78:1202-1207.
82. Hewison M., Kantorovich V., Liker H.R., Van Herle A.J., Cohan P., Zehnder D., et al. Vitamin D-mediated hypercalcemia in lymphoma: evidence for hormone production by tumor-adjacent macrophages. J. Bone Miner. Res. 2003, 18:579-582.
83. Gates S., Shary J., Turner R.T., Wallach S., Bell N.H. Abnormal calcium metabolism caused by increased circulating 1,25-dihydroxyvitamin D in a patient with rheumatoid arthritis. J. Bone Miner. Res. 1986, 1:221-226.
84. Kroger H., Penttila I.M., Alhava E.M. Low serum vitamin D metabolites in women with rheumatoid arthritis. Scand. J. Rheumatol. 1993, 22:172-177.
85. Oelzner P., Muller A., Deschner F., Huller M., Abendroth K., Hein G., et al. Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. Calcif. Tissue Int. 1998, 62:193-198.
86. Muller K., Kriegbaum N.J., Baslund B., Sorensen O.H., Thymann M., Bentzen K. Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus. Clin. Rheumatol. 1995, 14:397-400.
87. Cutillas-Marco E., Morales-Suarez-Varela M., Marquina-Vila A., Grant W. Serum 25-hydroxyvitamin D levels in patients with cutaneous lupus erythematosus in a Mediterranean region. Lupus 2010, 19:810-814.
88. Cutolo M., Otsa K. Review: vitamin D, immunity and lupus. Lupus 2008, 17:6-10.
89. Kamen D., Aranow C. Vitamin D in systemic lupus erythematosus. Curr. Opin. Rheumatol. 2008, 20:532-537.
90. Hayes M.E., Denton J., Freemont A.J., Mawer E.B. Synthesis of the active metabolite of vitamin D, 1,25(OH)2D3, by synovial fluid macrophages in arthritic diseases. Ann. Rheum. Dis. 1989, 48:723-729.
91. Mawer E.B., Hayes M.E., Still P.E., Davies M., Lumb G.A., Palit J., et al. Evidence for nonrenal synthesis of 1,25-dihydroxyvitamin D in patients with inflammatory arthritis. J. Bone Miner. Res. 1991, 6:733-739.
92. Hayes M.E., O'Donoghue D.J., Ballardie F.W., Mawer E.B. Peritonitis induces the synthesis of 1 alpha,25-dihydroxyvitamin D3 in macrophages from CAPD patients. FEBS Lett. 1987, 220:307-310.
93. Levy R., Klein J., Rubinek T., Alkan M., Shany S., Chaimovitz C. Diversity in peritoneal macrophage response of CAPD patients to 1,25-dihydroxyvitamin D3. Kidney Int. 1990, 37:1310-1315.
94. Shany S., Rapoport J., Zuili I., Gavriel A., Lavi N., Chaimovitz C. Metabolism of 25-OH-vitamin D3 by peritoneal macrophages from CAPD patients. Kidney Int. 1991, 39:1005-1011.
95. Fu G.K., Lin D., Zhang M.Y., Bikle D.D., Shackleton C.H., Miller W.L., et al. Cloning of human 25-hydroxyvitamin D-1 alpha-hydroxylase and mutations causing vitamin D-dependent rickets type 1. Mol. Endocrinol. 1997, 11:1961-1970.
96. Zehnder D., Bland R., Walker E.A., Bradwell A.R., Howie A.J., Hewison M., et al. Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in the human kidney. J. Am. Soc. Nephrol. 1999, 10:2465-2473.
97. Hewison M., Burke F., Evans K.N., Lammas D.A., Sansom D.M., Liu P., et al. Extra-renal 25-hydroxyvitamin D3-1alpha-hydroxylase in human health and disease. J. Steroid Biochem. Mol. Biol. 2007, 103:316-321.
98. Panda D.K., Miao D., Tremblay M.L., Sirois J., Farookhi R., Hendy G.N., et al. Targeted ablation of the 25-hydroxyvitamin D 1alpha-hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc. Natl. Acad. Sci. USA 2001, 98:7498-7503.
99. Vanhooke J.L., Prahl J.M., Kimmel-Jehan C., Mendelsohn M., Danielson E.W., Healy K.D., et al. CYP27B1 null mice with LacZreporter gene display no 25-hydroxyvitamin D3-1{alpha}-hydroxylase promoter activity in the skin. Proc. Natl. Acad. Sci. USA 2006, 103:75-80.
100. Abe E., Miyaura C., Sakagami H., Takeda M., Konno K., Yamazaki T., et al. Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. Proc. Natl. Acad. Sci. USA 1981, 78:4990-4994.
101. Abe E., Miyaura C., Tanaka H., Shiina Y., Kuribayashi T., Suda S., et al. 1 Alpha,25-dihydroxyvitamin D3 promotes fusion of mouse alveolar macrophages both by a direct mechanism and by a spleen cell-mediated indirect mechanism. Proc. Natl. Acad. Sci. USA 1983, 80:5583-5587.
102. Tanaka H., Abe E., Miyaura C., Shiina Y., Suda T. 1 Alpha,25-dihydroxyvitamin D3 induces differentiation of human promyelocytic leukemia cells (HL-60) into monocyte-macrophages, but not into granulocytes. Biochem. Biophys. Res. Commun. 1983, 117:86-92.
103. Koeffler H.P., Amatruda T., Ikekawa N., Kobayashi Y., DeLuca H.F. Induction of macrophage differentiation of human normal and leukemic myeloid stem cells by 1,25-dihydroxyvitamin D3 and its fluorinated analogues. Cancer Res. 1984, 44:5624-5628.
104. Kreutz M., Andreesen R., Krause S.W., Szabo A., Ritz E., Reichel H. 1,25-Dihydroxyvitamin D3 production and vitamin D3 receptor expression are developmentally regulated during differentiation of human monocytes into macrophages. Blood 1993, 82:1300-1307.
105. Koeffler H.P., Reichel H., Bishop J.E., Norman A.W. Gamma-interferon stimulates production of 1,25-dihydroxyvitamin D3 by normal human macrophages. Biochem. Biophys. Res. Commun. 1985, 127:596-603.
106. Hewison M., Barker S., Brennan A., Nathan J., Katz D.R., O'Riordan J.L. Autocrine regulation of 1,25-dihydroxycholecalciferol metabolism in myelomonocytic cells. Immunology 1989, 68:247-252.
107. Liu P.T., Stenger S., Li H., Wenzel L., Tan B.H., Krutzik S.R., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311:1770-1773.
108. Adams J.S., Ren S., Liu P.T., Chun R.F., Lagishetty V., Gombart A.F., et al. Vitamin D-directed rheostatic regulation of monocyte antibacterial responses. J. Immunol. 2009, 182:4289-4295.
109. Brennan A., Katz D.R., Nunn J.D., Barker S., Hewison M., Fraher L.J., et al. Dendritic cells from human tissues express receptors for the immunoregulatory vitamin D3 metabolite, dihydroxycholecalciferol. Immunology 1987, 61:457-461.
110. Hewison M., Freeman L., Hughes S.V., Evans K.N., Bland R., Eliopoulos A.G., et al. Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J. Immunol. 2003, 170:5382-5390.
111. Fritsche J., Mondal K., Ehrnsperger A., Andreesen R., Kreutz M. Regulation of 25-hydroxyvitamin D3-1 alpha-hydroxylase and production of 1 alpha,25-dihydroxyvitamin D3 by human dendritic cells. Blood 2003, 102:3314-3316.
112. Hewison M., Zehnder D., Chakraverty R., Adams J.S. Vitamin D and barrier function: a novel role for extra-renal 1 alpha-hydroxylase. Mol. Cell Endocrinol. 2004, 215:31-38.
113. Sigmundsdottir H., Pan J., Debes G.F., Alt C., Habtezion A., Soler D., et al. DCs metabolize sunlight-induced vitamin D3 to "program" T cell attraction to the epidermal chemokine CCL27. Nat. Immunol. 2007, 8:285-293.
114. Chen S., Sims G.P., Chen X.X., Gu Y.Y., Chen S., Lipsky P.E. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J. Immunol. 2007, 179:1634-1647.
115. Gray T.K., Lester G.E., Lorenc R.S. Evidence for extra-renal 1 alpha-hydroxylation of 25-hydroxyvitamin D3 in pregnancy. Science 1979, 204:1311-1313.
116. Weisman Y., Harell A., Edelstein S., David M., Spirer Z., Golander A. 1 Alpha, 25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 in vitro synthesis by human decidua and placenta. Nature 1979, 281:317-319.
117. Zehnder D., Evans K.N., Kilby M.D., Bulmer J.N., Innes B.A., Stewart P.M., et al. The ontogeny of 25-hydroxyvitamin D(3) 1alpha-hydroxylase expression in human placenta and decidua. Am. J. Pathol. 2002, 161:105-114.
118. Evans K.N., Bulmer J.N., Kilby M.D., Hewison M. Vitamin D and placental-decidual function. J. Soc. Gynecol. Investig. 2004, 11:263-271.
119. Novakovic B., Sibson M., Ng H.K., Manuelpillai U., Rakyan V., Down T., et al. Placenta-specific methylation of the vitamin D 24-hydroxylase gene: implications for feedback autoregulation of active vitamin D levels at the fetomaternal interface. J. Biol. Chem. 2009, 284:14838-14848.
120. Kovacs C.S., Kronenberg H.M. Maternal-fetal calcium and bone metabolism during pregnancy, puerperium, and lactation. Endocr. Rev. 1997, 18:832-872.
121. Bruns M.E., Bruns D.E. Vitamin D metabolism and function during pregnancy and the neonatal period. Ann. Clin. Lab. Sci. 1983, 13:521-530.
122. Rebut-Bonneton C., Demignon J. Effects of 1,25-dihydroxyvitamin D3 on in vitro lymphocyte reactions: arguments for a role at the maternofetal interface. Gynecol. Obstet. Invest. 1991, 32:134-138.
123. Sacks G., Sargent I., Redman C. Innate immunity in pregnancy. Immunol. Today 2000, 21:200-201.
124. Sacks G., Sargent I., Redman C. An innate view of human pregnancy. Immunol. Today 1999, 20:114-118.
125. Guleria I., Pollard J.W. The trophoblast is a component of the innate immune system during pregnancy. Nat. Med. 2000, 6:589-593.
126. Zenclussen A.C., Schumacher A., Zenclussen M.L., Wafula P., Volk H.D. Immunology of pregnancy: cellular mechanisms allowing fetal survival within the maternal uterus. Expert Rev. Mol. Med. 2007, 9:1-14.
127. Laskarin G., Kammerer U., Rukavina D., Thomson A.W., Fernandez N., Blois S.M. Antigen-presenting cells and materno-fetal tolerance: an emerging role for dendritic cells. Am. J. Reprod. Immunol. 2007, 58:255-267.
128. Fischer D., Schroer A., Ludders D., Cordes T., Bucker B., Reichrath J., et al. Metabolism of vitamin D3 in the placental tissue of normal and preeclampsia complicated pregnancies and premature births. Clin. Exp. Obstet. Gynecol. 2007, 34:80-84.
129. Diaz L., Arranz C., Avila E., Halhali A., Vilchis F., Larrea F. Expression and activity of 25-hydroxyvitamin D-1 alpha-hydroxylase are restricted in cultures of human syncytiotrophoblast cells from preeclamptic pregnancies. J. Clin. Endocrinol. Metab. 2002, 87:3876-3882.
130. Bodnar L.M., Catov J.M., Simhan H.N., Holick M.F., Powers R.W., Roberts J.M. Maternal vitamin D deficiency increases the risk of preeclampsia. J. Clin. Endocrinol. Metab. 2007.
131. Bodnar L.M., Simhan H.N., Powers R.W., Frank M.P., Cooperstein E., Roberts J.M. High prevalence of vitamin D insufficiency in black and white pregnant women residing in the northern United States and their neonates. J. Nutr. 2007, 137:447-452.
132. Hypponen E. Vitamin D for the prevention of preeclampsia? A hypothesis. Nutr. Rev. 2005, 63:225-232.
133. Bikle D.D., Pillai S., Gee E., Hincenbergs M. Regulation of 1,25-dihydroxyvitamin D production in human keratinocytes by interferon-gamma. Endocrinology 1989, 124:655-660.
134. Pillai S., Bikle D.D., Elias P.M. 1,25-Dihydroxyvitamin D production and receptor binding in human keratinocytes varies with differentiation. J. Biol. Chem. 1988, 263:5390-5395.
135. Bikle D.D., Chang S., Crumrine D., Elalieh H., Man M.Q., Dardenne O., et al. Mice lacking 25OHD 1alpha-hydroxylase demonstrate decreased epidermal differentiation and barrier function. J. Steroid Biochem. Mol. Biol. 2004, 89-90:347-353.
136. Bikle D.D., Chang S., Crumrine D., Elalieh H., Man M.Q., Choi E.H., et al. 25 Hydroxyvitamin D 1 alpha-hydroxylase is required for optimal epidermal differentiation and permeability barrier homeostasis. J. Invest. Dermatol. 2004, 122:984-992.
137. Segersten U., Correa P., Hewison M., Hellman P., Dralle H., Carling T., et al. 25-Hydroxyvitamin D(3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands. J. Clin. Endocrinol. Metab. 2002, 87:2967-2972.
138. Correa P., Segersten U., Hellman P., Akerstrom G., Westin G. Increased 25-hydroxyvitamin D3 1alpha-hydroxylase and reduced 25-hydroxyvitamin D3 24-hydroxylase expression in parathyroid tumors - new prospects for treatment of hyperparathyroidism with vitamin D. J. Clin. Endocrinol. Metab. 2002, 87:5826-5829.
139. Krajisnik T., Bjorklund P., Marsell R., Ljunggren O., Akerstrom G., Jonsson K.B., et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J. Endocrinol. 2007, 195:125-131.
140. Ritter C.S., Armbrecht H.J., Slatopolsky E., Brown A.J. 25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int. 2006, 70:654-659.
141. Kawahara M., Iwasaki Y., Sakaguchi K., Taguchi T., Nishiyama M., Nigawara T., et al. Predominant role of 25OHD in the negative regulation of PTH expression: clinical relevance for hypovitaminosis D. Life Sci. 2008, 82:677-683.
142. Lauter K., Arnold A. Analysis of CYP27B1, encoding 25-hydroxyvitamin D-1alpha-hydroxylase, as a candidate tumor suppressor gene in primary and severe secondary/tertiary hyperparathyroidism. J. Bone Miner. Res. 2009, 24:102-104.
143. Bland R., Markovic D., Hills C.E., Hughes S.V., Chan S.L., Squires P.E., et al. Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in pancreatic islets. J. Steroid Biochem. Mol. Biol. 2004, 89-90:121-125.
144. P.S. Leung, Q. Cheng, The novel roles of glucagon-like peptide-1, angiotensin II, and vitamin D in islet function. Adv. Exp. Med. Biol. 654:339-361.
145. Mathieu C., Gysemans C., Giulietti A., Bouillon R. Vitamin D and diabetes. Diabetologia 2005, 48:1247-1257.
146. Khadzkou K., Buchwald P., Westin G., Dralle H., Akerstrom G., Hellman P. 25-Hydroxyvitamin D3 1alpha-hydroxylase and vitamin D receptor expression in papillary thyroid carcinoma. J. Histochem. Cytochem. 2006, 54:355-361.
147. Blomberg Jensen M., Nielsen J.E., Jorgensen A., Rajpert-De Meyts E., Kristensen D.M., Jorgensen N., et al. Vitamin D receptor and vitamin D metabolizing enzymes are expressed in the human male reproductive tract. Hum. Reprod 2010, 25:1303-1311.
148. Kinuta K., Tanaka H., Moriwake T., Aya K., Kato S., Seino Y. Vitamin D is an important factor in estrogen biosynthesis of both female and male gonads. Endocrinology 2000, 141:1317-1324.
149. Hughes S.V., Robinson E., Bland R., Lewis H.M., Stewart P.M., Hewison M. 1,25-Dihydroxyvitamin D3 regulates estrogen metabolism in cultured keratinocytes. Endocrinology 1997, 138:3711-3718.
150. Fischer D., Thome M., Becker S., Cordes T., Diedrich K., Friedrich M., et al. Expression of 25-hydroxyvitamin D3-24-hydroxylase in benign and malignant ovarian cell lines and tissue. Anticancer Res. 2009, 29:3635-3639.
151. Evans K.N., Taylor H., Zehnder D., Kilby M.D., Bulmer J.N., Shah F., et al. Increased expression of 25-hydroxyvitamin D-1alpha-hydroxylase in dysgerminomas: a novel form of humoral hypercalcemia of malignancy. Am. J. Pathol. 2004, 165:807-813.
152. Friedrich M., Rafi L., Mitschele T., Tilgen W., Schmidt W., Reichrath J. Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Recent Results Cancer Res. 2003, 164:239-246.
153. Agic A., Xu H., Altgassen C., Noack F., Wolfler M.M., Diedrich K., et al. Relative expression of 1,25-dihydroxyvitamin D3 receptor, vitamin D 1 alpha-hydroxylase, vitamin D 24-hydroxylase, and vitamin D 25-hydroxylase in endometriosis and gynecologic cancers. Reprod. Sci. 2007, 14:486-497.
154. Schwartz G.G., Whitlatch L.W., Chen T.C., Lokeshwar B.L., Holick M.F. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol. Biomarkers Prev. 1998, 7:391-395.
155. Barreto A.M., Schwartz G.G., Woodruff R., Cramer S.D. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol. Biomarkers Prev. 2000, 9:265-270.
156. Polek T.C., Weigel N.L. Vitamin D and prostate cancer. J. Androl. 2002, 23:9-17.
157. Whitlatch L.W., Young M.V., Schwartz G.G., Flanagan J.N., Burnstein K.L., Lokeshwar B.L., et al. 25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J. Steroid Biochem. Mol. Biol. 2002, 81:135-140.
158. Hsu J.Y., Feldman D., McNeal J.E., Peehl D.M. Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res. 2001, 61:2852-2856.
159. Townsend K., Banwell C.M., Guy M., Colston K.W., Mansi J.L., Stewart P.M., et al. Autocrine metabolism of vitamin D in normal and malignant breast tissue. Clin. Cancer Res. 2005, 11:3579-3586.
160. Segersten U., Holm P.K., Bjorklund P., Hessman O., Nordgren H., Binderup L., et al. 25-Hydroxyvitamin D3 1alpha-hydroxylase expression in breast cancer and use of non-1alpha-hydroxylated vitamin D analogue. Breast Cancer Res. 2005, 7:R980-986.
161. Colston K.W., Lowe L.C., Mansi J.L., Campbell M.J. Vitamin D status and breast cancer risk. Anticancer Res. 2006, 26:2573-2580.
162. Kemmis C.M., Welsh J. Mammary epithelial cell transformation is associated with deregulation of the vitamin D pathway. J. Cell Biochem. 2008, 105:980-988.
163. Rowling M.J., Kemmis C.M., Taffany D.A., Welsh J. Megalin-mediated endocytosis of vitamin D binding protein correlates with 25-hydroxycholecalciferol actions in human mammary cells. J. Nutr. 2006, 136:2754-2759.
164. Nykjaer A., Dragun D., Walther D., Vorum H., Jacobsen C., Herz J., et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999, 96:507-515.
165. Welsh J. Vitamin D and breast cancer: insights from animal models. Am. J. Clin. Nutr. 2004, 80:1721S-1724S.
166. Zinser G.M., McEleney K., Welsh J. Characterization of mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice. Mol. Cell Endocrinol. 2003, 200:67-80.
167. Zinser G.M., Welsh J. Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice. Carcinogenesis 2004, 25:2361-2372.
168. Bischof M.G., Siu-Caldera M.L., Weiskopf A., Vouros P., Cross H.S., Peterlik M., et al. Differentiation-related pathways of 1 alpha,25-dihydroxycholecalciferol metabolism in human colon adenocarcinoma-derived Caco-2 cells: production of 1 alpha,25-dihydroxy-3epi-cholecalciferol. Exp. Cell Res. 1998, 241:194-201.
169. Lagishetty V., Chun R.F., Liu N.Q., Lisse T.S., Adams J.S., Hewison M. 1alpha-Hydroxylase and innate immune responses to 25-hydroxyvitamin D in colonic cell lines. J. Steroid Biochem. Mol. Biol. 2010, 121:228-233.
170. Bareis P., Kallay E., Bischof M.G., Bises G., Hofer H., Potzi C., et al. Clonal differences in expression of 25-hydroxyvitamin D(3)-1alpha-hydroxylase, of 25-hydroxyvitamin D(3)-24-hydroxylase, and of the vitamin D receptor in human colon carcinoma cells: effects of epidermal growth factor and 1alpha,25-dihydroxyvitamin D(3). Exp. Cell Res. 2002, 276:320-327.
171. Kallay E., Bises G., Bajna E., Bieglmayer C., Gerdenitsch W., Steffan I., et al. Colon-specific regulation of vitamin D hydroxylases - a possible approach for tumor prevention. Carcinogenesis 2005, 26:1581-1589.
172. Cross H.S., Bises G., Lechner D., Manhardt T., Kallay E. The Vitamin D endocrine system of the gut - its possible role in colorectal cancer prevention. J. Steroid Biochem. Mol. Biol. 2005, 97:121-128.
173. Peterlik M., Cross H.S. Dysfunction of the vitamin D endocrine system as common cause for multiple malignant and other chronic diseases. Anticancer Res. 2006, 26:2581-2588.
174. Liu N., Nguyen L., Chun R.F., Lagishetty V., Ren S., Wu S., et al. Altered endocrine and autocrine metabolism of vitamin D in a mouse model of gastrointestinal inflammation. Endocrinology 2008, 149:4799-4808.
175. Lagishetty V., Misharin A.V., Liu N.Q., Lisse T.S., Chun R.F., Ouyang Y., et al. Vitamin D deficiency in mice impairs colonic antibacterial activity and predisposes to colitis. Endocrinology 2010, 151:2423-2432.
176. Turner R.T., Puzas J.E., Forte M.D., Lester G.E., Gray T.K., Howard G.A., et al. In vitro synthesis of 1 alpha,25-dihydroxycholecalciferol and 24,25-dihydroxycholecalciferol by isolated calvarial cells. Proc. Natl. Acad. Sci. USA 1980, 77:5720-5724.
177. Howard G.A., Turner R.T., Sherrard D.J., Baylink D.J. Human bone cells in culture metabolize 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3. J. Biol. Chem. 1981, 256:7738-7740.
178. Pols H.A., Schilte H.P., Nijweide P.J., Visser T.J., Birkenhager J.C. The influence of albumin on vitamin D metabolism in fetal chick osteoblast-like cells. Biochem. Biophys. Res. Commun. 1984, 125:265-272.
179. van Driel M., Koedam M., Buurman C.J., Hewison M., Chiba H., Uitterlinden A.G., et al. Evidence for auto/paracrine actions of vitamin D in bone: 1alpha-hydroxylase expression and activity in human bone cells. Faseb J. 2006, 20:2417-2419.
180. Atkins G.J., Anderson P.H., Findlay D.M., Welldon K.J., Vincent C., Zannettino A.C., et al. Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1 alpha,25-dihydroxyvitamin D3. Bone 2007, 40:1517-1528.
181. Somjen D., Katzburg S., Stern N., Kohen F., Sharon O., Limor R., et al. 25 Hydroxy-vitamin D(3)-1alpha hydroxylase expression and activity in cultured human osteoblasts and their modulation by parathyroid hormone, estrogenic compounds and dihydrotestosterone. J. Steroid Biochem. Mol. Biol. 2007, 107:238-244.
182. Anderson P.H., Atkins G.J. The skeleton as an intracrine organ for vitamin D metabolism. Mol. Aspects. Med. 2008, 29:397-406.
183. St-Arnaud R. The direct role of vitamin D on bone homeostasis. Arch. Biochem. Biophys. 2008, 473:225-230.
184. Pedrozo H.A., Boyan B.D., Mazock J., Dean D.D., Gomez R., Schwartz Z. TGFbeta1 regulates 25-hydroxyvitamin D3 1alpha- and 24-hydroxylase activity in cultured growth plate chondrocytes in a maturation-dependent manner. Calcif. Tissue Int. 1999, 64:50-56.
185. Weber L., Hugel U., Reichrath J., Sieverts H., Mehls O., Klaus G. Cultured rat growth plate chondrocytes express low levels of 1alpha-hydroxylase. Recent Results Cancer Res. 2003, 164:147-149.
186. Schauber J., Dorschner R.A., Coda A.B., Buchau A.S., Liu P.T., Kiken D., et al. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J. Clin. Invest. 2007, 117:803-811.
187. St-Arnaud R., Dardenne O., Prud'homme J., Hacking S.A., Glorieux F.H. Conventional and tissue-specific inactivation of the 25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1). J. Cell Biochem. 2003, 88:245-251.
188. Naja R.P., Dardenne O., Arabian A., St Arnaud R. Chondrocyte-specific modulation of Cyp27b1 expression supports a role for local synthesis of 1,25-dihydroxyvitamin D3 in growth plate development. Endocrinology 2009, 150:4024-4032.
189. Takeyama K., Kitanaka S., Sato T., Kobori M., Yanagisawa J., Kato S. 25-Hydroxyvitamin D3 1alpha-hydroxylase and vitamin D synthesis. Science 1997, 277:1827-1830.
190. Shany S., Ren S.Y., Arbelle J.E., Clemens T.L., Adams J.S. Subcellular localization and partial purification of the 25-hydroxyvitamin D3 1-hydroxylation reaction in the chick myelomonocytic cell line HD-11. J. Bone Miner. Res. 1993, 8:269-276.
191. Adams J.S., Ren S.Y., Arbelle J.E., Horiuchi N., Gray R.W., Clemens T.L., et al. Regulated production and intracrine action of 1,25-dihydroxyvitamin D3 in the chick myelomonocytic cell line HD-11. Endocrinology 1994, 134:2567-2573.
192. Reichel H., Koeffler H.P., Norman A.W. Synthesis in vitro of 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 by interferon-gamma-stimulated normal human bone marrow and alveolar macrophages. J. Biol. Chem. 1987, 262:10931-10937.
193. Fraser D.R. Regulation of the metabolism of vitamin D. Physiol. Rev. 1980, 60:551-613.
194. Nakamura Y., Eto T.A., Taniguchi T., Miyamoto K., Nagatomo J., Shiotsuki H., et al. Purification and characterization of 25-hydroxyvitamin D3 1alpha-hydroxylase from rat kidney mitochondria. FEBS Lett. 1997, 419:45-48.
195. Inouye K., Sakaki T. Enzymatic studies on the key enzymes of vitamin D metabolism; 1 alpha-hydroxylase (CYP27B1) and 24-hydroxylase (CYP24). Biotechnol. Annu. Rev. 2001, 7:179-194.
196. Pearce S.H., Thakker R.V. The calcium-sensing receptor: insights into extracellular calcium homeostasis in health and disease. J. Endocrinol. 1997, 154:371-378.
197. Chattopadhyay N., Mithal A., Brown E.M. The calcium-sensing receptor: a window into the physiology and pathophysiology of mineral ion metabolism. Endocr. Rev. 1996, 17:289-307.
198. Garabedian M., Holick M.F., Deluca H.F., Boyle I.T. Control of 25-hydroxycholecalciferol metabolism by parathyroid glands. Proc. Natl. Acad. Sci. USA 1972, 69:1673-1676.
199. Murayama A., Takeyama K., Kitanaka S., Kodera Y., Hosoya T., Kato S. The promoter of the human 25-hydroxyvitamin D3 1 alpha-hydroxylase gene confers positive and negative responsiveness to PTH, calcitonin, and 1 alpha,25(OH)2D3. Biochem. Biophys. Res. Commun. 1998, 249:11-16.
200. Kong X.F., Zhu X.H., Pei Y.L., Jackson D.M., Holick M.F. Molecular cloning, characterization, and promoter analysis of the human 25-hydroxyvitamin D3-1alpha-hydroxylase gene. Proc. Natl. Acad. Sci. USA 1999, 96:6988-6993.
201. Henry H.L. Vitamin D hydroxylases. J. Cell Biochem. 1992, 49:4-9.
202. Henry H.L., Dutta C., Cunningham N., Blanchard R., Penny R., Tang C., et al. The cellular and molecular regulation of 1,25(OH)2D3 production. J. Steroid Biochem. Mol. Biol. 1992, 41:401-407.
203. Portale A.A., Halloran B.P., Murphy M.M., Morris R.C. Oral intake of phosphorus can determine the serum concentration of 1,25-dihydroxyvitamin D by determining its production rate in humans. J. Clin. Invest. 1986, 77:7-12.
204. Tenenhouse H.S., Martel J., Gauthier C., Zhang M.Y., Portale A.A. Renal expression of the sodium/phosphate cotransporter gene, Npt2, is not required for regulation of renal 1 alpha-hydroxylase by phosphate. Endocrinology 2001, 142:1124-1129.
205. Juppner H., Wolf M. Salusky FGF23: more than a regulator of renal phosphate handling?. J. Bone Miner. Res. 2010, 25:2091-2097.
206. Razzaque M.S. The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat. Rev. Endocrinol. 2009, 5:611-619.
207. Shimada T., Kakitani M., Yamazaki Y., Hasegawa H., Takeuchi Y., Fujita T., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 2004, 113:561-568.
208. Jurutka P.W., Bartik L., Whitfield G.K., Mathern D.R., Barthel T.K., Gurevich M., et al. Vitamin D receptor: key roles in bone mineral pathophysiology, molecular mechanism of action, and novel nutritional ligands. J. Bone Miner. Res. 2007, 22(Suppl. 2):V2-10.
209. Quarles L.D. Endocrine functions of bone in mineral metabolism regulation. J. Clin. Invest. 2008, 118:3820-3828.
210. Reichel H., Koeffler H.P., Barbers R., Norman A.W. Regulation of 1,25-dihydroxyvitamin D3 production by cultured alveolar macrophages from normal human donors and from patients with pulmonary sarcoidosis. J. Clin. Endocrinol. Metab. 1987, 65:1201-1209.
211. Hakeda Y., Hiura K., Sato T., Okazaki R., Matsumoto T., Ogata E., et al. Existence of parathyroid hormone binding sites on murine hemopoietic blast cells. Biochem. Biophys. Res. Commun. 1989, 163:1481-1486.
212. Yuan J.Y., Freemont A.J., Mawer E.B., Hayes M.E. Regulation of 1 alpha, 25-dihydroxyvitamin D3 synthesis in macrophages from arthritic joints by phorbol ester, dibutyryl-cAMP and calcium ionophore (A23187). FEBS Lett. 1992, 311:71-74.
213. Bland R., Walker E.A., Hughes S.V., Stewart P.M., Hewison M. Constitutive expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in a transformed human proximal tubule cell line: evidence for direct regulation of vitamin D metabolism by calcium. Endocrinology 1999, 140:2027-2034.
214. Nesbitt T., Drezner M.K. Insulin-like growth factor-I regulation of renal 25-hydroxyvitamin D-1-hydroxylase activity. Endocrinology 1993, 132:133-138.
215. Henry H.L. 25(OH)D3 metabolism in kidney cell cultures: lack of a direct effect of estradiol. Am. J. Physiol. 1981, 240:E119-124.
216. Adams N.D., Garthwaite T.L., Gray R.W., Hagen T.C., Lemann J. The interrelationships among prolactin, 1,25-dihydroxyvitamin D, and parathyroid hormone in humans. J. Clin. Endocrinol. Metab. 1979, 49:628-630.
217. Brixen K., Nielsen H.K., Bouillon R., Flyvbjerg A., Mosekilde L. Effects of short-term growth hormone treatment on PTH, calcitriol, thyroid hormones, insulin and glucagon. Acta Endocrinol. (Copenh.) 1992, 127:331-336.
218. Omdahl J.L., Morris H.A., May B.K. Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annu. Rev. Nutr. 2002, 22:139-166.
219. Omdahl J.L., Bobrovnikova E.A., Choe S., Dwivedi P.P., May B.K. Overview of regulatory cytochrome P450 enzymes of the vitamin D pathway. Steroids 2001, 66:381-389.
220. Ohyama Y., Noshiro M., Okuda K. Cloning and expression of cDNA encoding 25-hydroxyvitamin D3 24-hydroxylase. FEBS Lett. 1991, 278:195-198.
221. Chen K.S., Prahl J.M., DeLuca H.F. Isolation and expression of human 1,25-dihydroxyvitamin D3 24-hydroxylase cDNA. Proc. Natl. Acad. Sci. USA 1993, 90:4543-4547.
222. Zierold C., Mings J.A., DeLuca H.F. Regulation of 25-hydroxyvitamin D3-24-hydroxylase mRNA by 1,25-dihydroxyvitamin D3 and parathyroid hormone. J. Cell Biochem. 2003, 88:234-237.
223. Henry H.L. Regulation of the hydroxylation of 25-hydroxyvitamin D3 in vivo and in primary cultures of chick kidney cells. J. Biol. Chem. 1979, 254:2722-2729.
224. Ebert R., Schutze N., Adamski J., Jakob F. Vitamin D signaling is modulated on multiple levels in health and disease. Mol. Cell Endocrinol. 2006, 248:149-159.
225. Xie Z., Munson S.J., Huang N., Portale A.A., Miller W.L., Bikle D.D. The mechanism of 1,25-dihydroxyvitamin D(3) autoregulation in keratinocytes. J. Biol. Chem. 2002, 277:36987-36990.
226. Ren S., Nguyen L., Wu S., Encinas C., Adams J.S., Hewison M. Alternative splicing of vitamin D-24-hydroxylase: a novel mechanism for the regulation of extrarenal 1,25-dihydroxyvitamin D synthesis. J. Biol. Chem. 2005, 280:20604-20611.
227. Adams J.S., Chen H., Chun R., Ren S., Wu S., Gacad M., et al. Substrate and enzyme trafficking as a means of regulating 1,25-dihydroxyvitamin D synthesis and action: the human innate immune response. J. Bone Miner. Res. 2007, 22(Suppl. 2):V20-24.
228. Adams J.S., Gacad M.A., Singer F.R., Sharma O.P. Production of 1,25-dihydroxyvitamin D3 by pulmonary alveolar macrophages from patients with sarcoidosis. Ann. N.Y. Acad. Sci. 1986, 465:587-594.
229. Adams J.S., Modlin R.L., Diz M.M., Barnes P.F. Potentiation of the macrophage 25-hydroxyvitamin D-1-hydroxylation reaction by human tuberculous pleural effusion fluid. J. Clin. Endocrinol. Metab. 1989, 69:457-460.
230. Hunninghake G.W. Role of alveolar macrophage- and lung T cell-derived mediators in pulmonary sarcoidosis. Ann. N.Y. Acad. Sci. 1986, 465:82-90.
231. Platanias L.C., Fish E.N. Signaling pathways activated by interferons. Exp. Hematol. 1999, 27:1583-1592.
232. Imada K., Leonard W.J. The Jak-STAT pathway. Mol. Immunol. 2000, 37:1-11.
233. Ishihara K., Hirano T. Molecular basis of the cell specificity of cytokine action. Biochim. Biophys. Acta 2002, 1592:281-296.
234. Xaus J., Comalada M., Valledor A.F., Cardo M., Herrero C., Soler C., et al. Molecular mechanisms involved in macrophage survival, proliferation, activation or apoptosis. Immunobiology 2001, 204:543-550.
235. Stoffels K., Overbergh L., Giulietti A., Verlinden L., Bouillon R., Mathieu C. Immune regulation of 25-hydroxyvitamin-D(3)-1alpha-hydroxylase in human monocytes. J. Bone Miner. Res. 2006, 21:37-47.
236. Stoffels K., Overbergh L., Giulietti A., Verlinden L., Bouillon R., Mathieu C. Immune regulation of 25-hydroxyvitamin-D3-1alpha-hydroxylase in human monocytes. J. Bone Miner. Res. 2006, 21:37-47.
237. Stoffels K., Overbergh L., Bouillon R., Mathieu C. Immune regulation of 1alpha-hydroxylase in murine peritoneal macrophages: unravelling the IFNgamma pathway. J. Steroid Biochem. Mol. Biol. 2007, 103:567-571.
238. Celada A., Schreiber R.D. Role of protein kinase C and intracellular calcium mobilization in the induction of macrophage tumoricidal activity by interferon-gamma. J. Immunol. 1986, 137:2373-2379.
239. Wightman P.D., Humes J.L., Davies P., Bonney R.J. [Identification and characterization of two phospholipase A2 activities in resident mouse peritoneal macrophages]. Biochem. J. 1981, 195:427-433.
240. Wightman P.D., Dahlgren M.E., Bonney R.J. Protein kinase activation of phospholipase A2 in sonicates of mouse peritoneal macrophages. J. Biol. Chem. 1982, 257:6650-6652.
241. Adams J.S., Gacad M.A., Diz M.M., Nadler J.L. A role for endogenous arachidonate metabolites in the regulated expression of the 25-hydroxyvitamin D-1-hydroxylation reaction in cultured alveolar macrophages from patients with sarcoidosis. J. Clin. Endocrinol. Metab. 1990, 70:595-600.
242. Medzhitov R., Janeway C. The Toll receptor family and microbial recognition. Trends Microbiol. 2000, 8:452-456.
243. Trinchieri G., Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol. 2007, 7:179-190.
244. Krutzik S.R., Hewison M., Liu P.T., Robles J.A., Stenger S., Adams J.S., et al. IL-15 links TLR2/1-induced macrophage differentiation to the vitamin D-dependent antimicrobial pathway. J. Immunol. 2008, 181:7115-7120.
245. Agostini C., Semenzato G. Cytokines in sarcoidosis. Semin. Respir. Infect. 1998, 13:184-196.
246. Adams J.S., Ren S.Y., Arbelle J.E., Clemens T.L., Shany S. A role for nitric oxide in the regulated expression of the 25-hydroxy-vitamin D-1-hydroxylation reaction in the chick myelomonocytic cell line HD-11. Endocrinology 1994, 134:499-502.
247. Adams J.S., Ren S.Y., Arbelle J.E., Shany S., Gacad M.A. Coordinate regulation of nitric oxide and 1,25-dihydroxyvitamin D production in the avian myelomonocytic cell line HD-11. Endocrinology 1995, 136:2262-2269.
248. Adams J.S., Ren S.Y. Autoregulation of 1,25-dihydroxyvitamin D synthesis in macrophage mitochondria by nitric oxide. Endocrinology 1996, 137:4514-4517.
249. Nathan C., Xie Q.W. Nitric oxide synthases: roles, tolls, and controls. Cell 1994, 78:915-918.
250. Snyder S.H. Nitric oxide: first in a new class of neurotransmitters. Science 1992, 257:494-496.
251. Salkowski C.A., Detore G., McNally R., van Rooijen N., Vogel S.N. Regulation of inducible nitric oxide synthase messenger RNA expression and nitric oxide production by lipopolysaccharide in vivo: the roles of macrophages, endogenous IFN-gamma, and TNF receptor-1-mediated signaling. J. Immunol. 1997, 158:905-912.
252. Alley E.W., Murphy W.J., Russell S.W. A classical enhancer element responsive to both lipopolysaccharide and interferon-gamma augments induction of the iNOS gene in mouse macrophages. Gene 1995, 158:247-251.
253. White K.A., Marletta M.A. Nitric oxide synthase is a cytochrome P-450 type hemoprotein. Biochemistry 1992, 31:6627-6631.
254. Khatsenko O.G., Gross S.S., Rifkind A.B., Vane J.R. Nitric oxide is a mediator of the decrease in cytochrome P450-dependent metabolism caused by immunostimulants. Proc. Natl. Acad. Sci. USA 1993, 90:11147-11151.
255. Stadler J., Trockfeld J., Schmalix W.A., Brill T., Siewert J.R., Greim H., et al. Inhibition of cytochromes P4501A by nitric oxide. Proc. Natl. Acad. Sci. USA 1994, 91:3559-3563.
256. Van Voorhis B.J., Dunn M.S., Snyder G.D., Weiner C.P. Nitric oxide: an autocrine regulator of human granulosa-luteal cell steroidogenesis. Endocrinology 1994, 135:1799-1806.
257. Enioutina E.Y., Bareyan D., Daynes R.A. TLR ligands that stimulate the metabolism of vitamin D3 in activated murine dendritic cells can function as effective mucosal adjuvants to subcutaneously administered vaccines. Vaccine 2008, 26:601-613.
258. Enioutina E.Y., Bareyan D., Daynes R.A. TLR-induced local metabolism of vitamin D3 plays an important role in the diversification of adaptive immune responses. J. Immunol. 2009, 182:4296-4305.
259. Takeda K., Akira S. Toll-like receptors in innate immunity. Int. Immunol. 2005, 17:1-14.
260. Casella C.R., Mitchell T.C. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol. Life Sci. 2008, 65:3231-3240.
261. Mata-Haro V., Cekic C., Martin M., Chilton P.M., Casella C.R., Mitchell T.C. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007, 316:1628-1632.
262. Sadeghi K., Wessner B., Laggner U., Ploder M., Tamandl D., Friedl J., et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur. J. Immunol. 2006, 36:361-370.
263. Feldman D. Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocr. Rev. 1986, 7:409-420.
264. Glass A.R., Cerletty J.M., Elliott W., Lemann J., Gray R.W., Eil C. Ketoconazole reduces elevated serum levels of 1,25-dihydroxyvitamin D in hypercalcemic sarcoidosis. J. Endocrinol. Invest. 1990, 13:407-413.
265. Glass A.R., Eil C. Ketoconazole-induced reduction in serum 1,25-dihydroxyvitamin D. J. Clin. Endocrinol. Metab. 1986, 63:766-769.
266. Pont A., Williams P.L., Loose D.S., Feldman D., Reitz R.E., Bochra C., et al. Ketoconazole blocks adrenal steroid synthesis. Ann. Intern. Med. 1982, 97:370-372.
267. Adams J.S., Lee G. Gains in bone mineral density with resolution of vitamin D intoxication. Ann. Intern. Med. 1997, 127:203-206.
268. R.F. Chun, A.L. Lauridsen, L. Suon, L.A. Zella, J.W. Pike, R.L. Modlin, et al., Vitamin D-binding protein directs monocyte responses to 25-hydroxy- and 1,25-dihydroxyvitamin D. J. Clin. Endocrinol. Metab. 95:3368-3376.
269. Peces R., Pobes A., Diaz-Corte C., Gago E. Hypercalcemia, inappropriate calcitriol levels, and tuberculosis on hemodialysis. Scand. J. Urol. Nephrol. 2000, 34:287-288.
270. Couri C.E., Foss N.T., Dos Santos C.S., de Paula F.J. Hypercalcemia secondary to leprosy. Am. J. Med. Sci. 2004, 328:357-359.
271. Wang I.K., Shen T.Y., Lee K.F., Chang H.Y., Lin C.L., Chuang F.R. Hypercalcemia and elevated serum 1.25-dihydroxyvitamin D in an end-stage renal disease patient with pulmonary cryptococcosis. Ren. Fail. 2004, 26:333-338.
272. Ali M.Y., Gopal K.V., Llerena L.A., Taylor H.C. Hypercalcemia associated with infection by Cryptococcus neoformans and Coccidioides immitis. Am. J. Med. Sci. 1999, 318:419-423.
273. Liang K.V., Ryu J.H., Matteson E.L. Histoplasmosis with tenosynovitis of the hand and hypercalcemia mimicking sarcoidosis. J. Clin. Rheumatol. 2004, 10:138-142.
274. Bosch X. Hypercalcemia due to endogenous overproduction of active vitamin D in identical twins with cat-scratch disease. Jama 1998, 279:532-534.
275. Playford E.G., Bansal A.S., Looke D.F., Whitby M., Hogan P.G. Hypercalcaemia and elevated 1,25(OH)(2)D(3) levels associated with disseminated Mycobacterium avium infection in AIDS. J. Infect. 2001, 42:157-158.
276. Delahunt J.W., Romeril K.E. Hypercalcemia in a patient with the acquired immunodeficiency syndrome and Mycobacterium avium intracellulare infection. J. Acquir. Immune. Defic. Syndr. 1994, 7:871-872.
277. Shaker J.L., Redlin K.C., Warren G.V., Findling J.W. Case report: hypercalcemia with inappropriate 1,25-dihydroxyvitamin D in Wegener's granulomatosis. Am. J. Med. Sci. 1994, 308:115-118.
278. Bosch X., Lopez-Soto A., Morello A., Olmo A., Urbano-Marquez A. Vitamin D metabolite-mediated hypercalcemia in Wegener's granulomatosis. Mayo. Clin. Proc. 1997, 72:440-444.
279. Sharma O.P. Hypercalcemia in granulomatous disorders: a clinical review. Curr. Opin. Pulm. Med. 2000, 6:442-447.
280. Greenaway T.M., Caterson I.D. Hypercalcemia and lipoid pneumonia. Aust. N.Z. J. Med. 1989, 19:713-715.
281. Rolla A.R., Granfone A., Balogh K., Khettry U., Davis B.L. Granuloma-related hypercalcemia in lipoid pneumonia. Am. J. Med. Sci. 1986, 292:313-316.
282. Woywodt A., Schneider W., Goebel U., Luft F.C. Hypercalcemia due to talc granulomatosis. Chest 2000, 117:1195-1196.
283. Karakelides H., Geller J.L., Schroeter A.L., Chen H., Behn P.S., Adams J.S., et al. Vitamin D-mediated hypercalcemia in slack skin disease: evidence for involvement of extrarenal 25-hydroxyvitamin D 1alpha-hydroxylase. J. Bone Miner. Res. 2006, 21:1496-1499.
284. Helikson M.A., Havey A.D., Zerwekh J.E., Breslau N.A., Gardner D.W. Plasma-cell granuloma producing calcitriol and hypercalcemia. Ann. Intern. Med. 1986, 105:379-381.
285. Hibi M., Hara F., Tomishige H., Nishida Y., Kato T., Okumura N., et al. 1,25-Dihydroxyvitamin D-mediated hypercalcemia in ovarian dysgerminoma. Pediatr. Hematol. Oncol. 2008, 25:73-78.
286. Grote T.H., Hainsworth J.D. Hypercalcemia and elevated serum calcitriol in a patient with seminoma. Arch. Intern. Med. 1987, 147:2212-2213.
287. Brunette M.G., Chan M., Ferriere C., Roberts K.D. Site of 1,25(OH)2 vitamin D3 synthesis in the kidney. Nature 1978, 276:287-289.
288. Bland R., Zehnder D., Hughes S.V., Ronco P.M., Stewart P.M., Hewison M. Regulation of vitamin D-1alpha-hydroxylase in a human cortical collecting duct cell line. Kidney Int. 2001, 60:1277-1286.
289. Bikle D.D., Nemanic M.K., Gee E., Elias P. 1,25-Dihydroxyvitamin D3 production by human keratinocytes. Kinetics and regulation. J. Clin. Invest. 1986, 78:557-566.
290. Bises G., Kallay E., Weiland T., Wrba F., Wenzl E., Bonner E., et al. 25-Hydroxyvitamin D3-1alpha-hydroxylase expression in normal and malignant human colon. J. Histochem. Cytochem. 2004, 52:985-989.
291. Ichikawa F., Sato K., Nanjo M., Nishii Y., Shinki T., Takahashi N., et al. Mouse primary osteoblasts express vitamin D3 25-hydroxylase mRNA and convert 1 alpha-hydroxyvitamin D3 into 1 alpha,25-dihydroxyvitamin D3. Bone 1995, 16:129-135.
292. Zehnder D., Bland R., Chana R.S., Wheeler D.C., Howie A.J., Williams M.C., et al. Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J. Am. Soc. Nephrol. 2002, 13:621-629.
293. Ma J.F., Nonn L., Campbell M.J., Hewison M., Feldman D., Peehl D.M. Mechanisms of decreased Vitamin D 1alpha-hydroxylase activity in prostate cancer cells. Mol. Cell Endocrinol. 2004, 221:67-74.
294. Chen T.C., Wang L., Whitlatch L.W., Flanagan J.N., Holick M.F. Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer. J. Cell Biochem. 2003, 88:315-322.
295. Bieche I., Narjoz C., Asselah T., Vacher S., Marcellin P., Lidereau R., et al. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet. Genomics 2007, 17:731-742.
296. Eyles D.W., Smith S., Kinobe R., Hewison M., McGrath J.J. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J. Chem. Neuroanat. 2005, 29:21-30.
297. Somjen D., Weisman Y., Kohen F., Gayer B., Limor R., Sharon O., et al. 25-Hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 2005, 111:1666-1671.